Home/Tolremo Therapeutics/Claudia Escher, PhD

CE

Claudia Escher, PhD

COO

Tolremo Therapeutics

Therapeutic Areas

Tolremo Therapeutics Pipeline

Drug	Indication	Phase
TT125-802	Solid tumors and hematological malignancies (for prevention of resistance)	Phase 1

Leadership Team at Tolremo Therapeutics

Stefanie Flückiger-Mangual, PhD

Alessandra Cesano, MD, PhD

Chief Medical Officer

Chief Business Officer

Julie M. Cherrington, PhD

Chair of the Board

View full Tolremo Therapeutics profile